BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Global Biodefense
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20190310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20191103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200316
DTEND;VALUE=DATE:20200318
DTSTAMP:20200223T181226Z
CREATED:20200223T173102Z
LAST-MODIFIED:20200223T181226Z
UID:40151-1584316800-1584489599@globalbiodefense.com
SUMMARY:IABS-CEPI Vaccine Technology Platforms Meeting
DESCRIPTION:A cross-learning symposium on vaccine licensure based on technology platforms\, the IABS-CEPI-ZAPI Technology Platforms Meeting\, will take place 16-17 March 2020 in Brussels\, Belgium. \nThe scientific committee for this workshop is co-Chaired by: \n\nDaniel Brasseur\, former CHMP-PDCO-VWP chair at EMA; CEPI consultant\nMurray Lumpkin\, former Deputy Director\, FDA; Bill & Melinda Gates Foundation\n\nHighlighted topics of interest on the agenda include: \n\nWHO regulatory preparedness activities to facilitate access to emergency vaccines\nHuman influenza vaccine successes and failures\nLessons for emergency preparedness leaned from Ebola vaccine development and licensure\nRegulatory approach to vaccine tech platforms: FDA perspective\, EU approach\, AVAREF\, Asian regulators\nAdvanced human vaccines in the pipeline (viral vectors\, VSV-Measles-ChAd…) and RNA\, DNA technologies\nTo what extent can clinical trials be pre-arranged?\nDetermining what is platform generic vs. platform specific in manufacturing and quality control\nChallenges to prove vaccine efficacy for outbreak vaccines and mitigating risk\nStreamlining regulatory acceptance from ‘tried and true’ vaccine platforms\n\nIn addition\, CEPI will review its current portfolio and examples of vaccine candidates based on technology platforms. \nMembers of the Scientific Committee include: \n\nDr. Barney Graham\, NIH\, Deputy Director and Chief\, Viral Pathogenesis Laboratory\nDr. Mélanie Saville\, Director\, Vaccine Development\, CEPI\nProf. Dr. Johan Neyts\, Rega Institute Louvain\, Belgium\, specialist of DNA vaccine PLLAV\nDr. Marion Gruber\, FDA\, Director\, Office of Vaccine Research and Review – CBER\nDr. Ivo Classen\, EMA\, Head of Veterinary Medicines Division\nDr. Marco Cavaleri\, EMA\, Head of Anti-infectives and Vaccines\nProf Dr. Jeffery Almond\, Oxford University; Chairman of the Board\, Osivax\nDr. Jean-Christophe Audonnet\, Senior Director\, Vaccines R&D; ZAPI Project Coordinator;\nBoehringer Ingelheim Animal Health\nDr. Emmanuel Hanon\, Senior Vice President\, Head of R&D\, GSK Vaccines\nDr Ajoy Chakrabarti\, Bill & Melinda Gates Foundation Vaccine Development\nDr Steve Black\, The Brighton Collaboration\, Task Force for Global Health\n\nRegister now for the IABS-CEPI Technology Platforms Meeting
URL:https://globalbiodefense.com/event/iabs-cepi-vaccine-technology-platforms-meeting/
CATEGORIES:Conference,Industry Day
END:VEVENT
END:VCALENDAR